| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | ALNYLAM PHARMACEUTICALS, INC. | 11,943,895 | 9.5% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | ALNYLAM PHARMACEUTICALS, INC. | 10,342,397 | 8.2% | EDGAR |
| SC 13G/A | 2024-02-09 | WELLINGTON MANAGEMENT GROUP LLP | ALNYLAM PHARMACEUTICALS, INC. | 7,252,907 | 5.8% | EDGAR |
| SC 13G/A | 2024-02-09 | Capital World Investors | ALNYLAM PHARMACEUTICALS, INC. | 16,398,889 | 13.1% | EDGAR |
| SC 13G/A | 2024-01-29 | BAILLIE GIFFORD & CO | ALNYLAM PHARMACEUTICALS, INC. | 6,967,097 | 5.6% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | ALNYLAM PHARMACEUTICALS, INC. | 8,546,557 | 6.8% | EDGAR |
| SC 13G/A | 2023-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | ALNYLAM PHARMACEUTICALS, INC. | 4,074,144 | 3.3% | EDGAR |
| SC 13G/A | 2023-02-13 | Capital World Investors | ALNYLAM PHARMACEUTICALS, INC. | 16,593,958 | 13.5% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | ALNYLAM PHARMACEUTICALS, INC. | 13,542,825 | 11.0% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | ALNYLAM PHARMACEUTICALS, INC. | 11,507,116 | 9.4% | EDGAR |
| SC 13G/A | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | ALNYLAM PHARMACEUTICALS, INC. | 6,261,642 | 5.1% | EDGAR |
| SC 13G/A | 2023-01-31 | BlackRock Inc. | ALNYLAM PHARMACEUTICALS, INC. | 8,665,702 | 7.0% | EDGAR |
| SC 13G/A | 2023-01-19 | BAILLIE GIFFORD & CO | ALNYLAM PHARMACEUTICALS, INC. | 9,407,871 | 7.6% | EDGAR |
| SC 13G | 2022-09-09 | Capital World Investors | ALNYLAM PHARMACEUTICALS, INC. | 12,816,777 | 10.7% | EDGAR |
| SC 13G | 2022-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | ALNYLAM PHARMACEUTICALS, INC. | 6,535,368 | 5.4% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | ALNYLAM PHARMACEUTICALS, INC. | 17,940,020 | 15.0% | EDGAR |
| SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | ALNYLAM PHARMACEUTICALS, INC. | 10,702,771 | 9.0% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | ALNYLAM PHARMACEUTICALS, INC. | 6,839,821 | 5.7% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | ALNYLAM PHARMACEUTICALS, INC. | 7,671,402 | 6.4% | EDGAR |
| SC 13G/A | 2022-01-18 | BAILLIE GIFFORD & CO | ALNYLAM PHARMACEUTICALS, INC. | 10,616,751 | 8.9% | EDGAR |